GENB Generate Biomedicines Inc

$GENB At the European Respiratory Society (ERS) Congress 2026, Generate will present three posters on GB-0895 in COPD and severe asthma. The COPD poster will present safety, pharmacokinetic, and pharmacodynamic data from the ongoing Phase 1b study in adults with COPD on Sept. 8. Two additional posters will present complete Phase 1 data in asthma and the design of the ongoing SOLAIRIA-1 and SOLAIRIA-2 replicate Phase 3 studies in severe asthma.

$GENB Bearish near-term. The −20.8% wasn't a verdict on the science — it was arithmetic: unlocking 68M shares onto a 60M-share float is dilution with extra steps.

$GENB Nvidia owns 833,325 shares of GENB and publicly backs its AI‑drug‑design platform $MRNA

$GENB Jumped out and took loss, looks like someone is pumped up for tomorrow, ending the lock-up period.

$GENB Joining the $GENB party 🎉 AI-driven protein design, GB-0895 already in Phase 3, Novartis partnership, and NVIDIA/NVentures backing. Definitely speculative, but there’s enough here to make this one interesting. Started a small position today. Let’s see where this goes. 👀🧬